Retrospective Analysis Of Biweekly Gemcitabine At Fixed Dose Rate Infusion Plus S-1 As First-Line Treatment For Advanced Pancreatic Cancer

Objective:The aim of our study is through a retrospective analysis efficiency and safety of biweekly gemcitabine at fixed dose rate infusion plus S-1 as first-line treatment for advanced pancreatic cancer,and analysis the factors influencing survival of patients with advanced pancreatic cancer.Methods:Collecting the detailed clinical data of patients with advanced pancreatic cancer diagnosed by pathology and imaging who received biweekly FGS regimen chemotherapy from January 2012 to December 2016 in Oncology Department of the First Affiliated Hospital of Nanchang University,including baseline characteristics,clinical efficacy and adverse reactions.analysis OS?PFS?ORR and DCR.SPSS22.0 was applied to statistical analysis.Log-rank tests and Kaplan-Meier estimations were performed for the analysis of OS.Differences were assumed to be significant when P<0.05.Cox proportional hazards modeling was used to examine the effect of various prognostic factors on OS and PFS according to the results of the univariate analysis.Results:A total of 43 patients were enrolled.The deadline for follow-up is 31 st December,2017.The median overall survival of patients is 10.2 months,1 years and 2 years survival rates were 39.5% and 11.6%.The median progression-free survival is 6.1 months and the ORR is 34.9%,the DCR is 79.1%.The main adverse reactions were myelosuppression,in which leukopenia and neutrophil decrease were more obvious,but the degree was mild,and the patient was well tolerated.Univariate analysis showed that ECOG score,presence or absence of liver metastasis,NLR level before treatment,tumor stage,second-line treatment,and the decrease of CA19-9 after treatment were prognostic factors affecting the overall survival time of patients with advanced pancreatic cancer,while ECOG score,presence or absence of liver metastasis,tumor stage and the decrease of CA19-9 after treatment were prognostic factors affecting the progression-free survival time of patients.Multivariate analysis showed that ECOG score,NLR level before treatment,whether to accept second-line treatment and the decrease of CA19-9 after treatment were independent prognostic factors affecting the overall survival time of patients with advanced pancreatic cancer,while ECOG score and the decrease level of CA19-9 after treatment were independent prognostic factors affecting the progression-free survival time of patients with advanced pancreatic cancer.Conclusion:FGS regimen was high effective and well tolerated in the first-line treatment of advanced pancreatic cancer.ECOG score,NLR level before treatment,and the decrease level of CA19-9 after treatment were independent prognostic factors for survival of these patients.